bepecin bpc-157 clinical trial Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Regeneration or Risk? A Narrative

17 July 2026 BPC-157 remains unapproved

Human growth hormones dictate things like our metabolism and body composition

b , Protein and cell-based screens to discover anti-CD38 UniAbs

Maurer M, Berger W, Gimnez-Arnau A, Hayama K, Jain V, Reich A, et al

Methods Patient selection The inclusion criteria for the patients were as follows: patients 1) with histologically or cytologically proven non-Sq NSCLC and MPM, 2) planning to use pemetrexed-containing chemotherapy, 3) nave or previously treated with chemotherapy, 4) with ECOG-PS of 02, 5) age 20 years, 6) with adequate organ function measured as leukocyte count 3,000 /L, hemoglobin concentration 10.0 g/dL, platelet count 100,000 /L, total bilirubin level 2.0 mg/dL, transaminase levels 100 IU/L, serum creatinine level 1.5 mg/dL, SpO 2 (percutaneous oxygen saturation) 90% in ambient air, 7) expected to survive at least 12 weeks from the start of treatment, and 8) who provided written informed consent